Outside the context of chemoresistance, there are several examples of exploiting the glutaminase activity of ASNase for targeting glutamine‐dependent cancer cells, including both solid [35, 42] and hematological cancer‐derived models [43, 44, 45]. The gene discussed is GLS; the disease is hematopoietic and lymphoid cell neoplasm.